DOCSLIB.ORG

HGF, Sil-6R and TGF-Β1 Play a Significant Role in the Progression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HGF, Sil-6R and TGF-Β1 Play a Significant Role in the Progression Journal of Cancer 2014, Vol. 5 518 Ivyspring International Publisher Journal of Cancer 2014; 5(7): 518-524. doi: 10.7150/jca.9266 Research Paper HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma Artur Jurczyszyn1, Jacek Czepiel2, Grażyna Biesiada2, Joanna Gdula-Argasińska3, Dorota Cibor2, Danuta Owczarek2, William Perucki4, Aleksander B. Skotnicki1 1. Department of Haematology, University Hospital, Kraków, Poland; 2. Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland; 3. Department of Radioligands, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland; 4. Students’ Scientific Society, Jagiellonian University Medical College, Kraków, Poland. Corresponding author: Artur Jurczyszyn, MD, PhD. Oddział Hematologii, Szpital Uniwersytecki, ul. Kopernika 17, 31-501 Kraków, Polska. Phone: 12 – 424-76-00, fax: 12-424-74-26 e-mail: [email protected]. © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2014.03.31; Accepted: 2014.05.22; Published: 2014.06.11 Abstract Background. In the last few years, it has been widely reported that proinflammatory and angi- ogenic cytokines are important for the development and progression of multiple myeloma (MM). Objectives. To further validate and acquire more insight into this view we decided to check whether plasma levels of certain cytokines and their soluble receptors differ between MM patients and healthy subjects. Patients and Methods. The study was conducted in 76 MM patients aged 22 to 77 years (60±10 years) and 35 healthy controls aged 20 to 63 years (33±10 years). Plasma levels of interleukin-6 (IL-6), b-fibroblast growth factor (b-FGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1), as well as soluble receptors for IL-6 (sIL-6R) and VEGF (sVEGF-R2) were measured using enzyme-linked immunosorbent assay (ELISA). Results. Significantly higher plasma levels of IL-6 (13.65±42.61 vs. 1.04±1.12 pg/ml, p=0.006), HGF (2174±2714 vs. 648±130 pg/ml, p<0.001), b-FGF (7.92±10.78 vs. 2.54±5.38 pg/ml, p<0.001) and sIL-6R (37.1±14.2 vs. 25.3±6.4 ng/ml, p=0.003) were observed in MM patients vs. healthy controls, respectively. Plasma sVEGF-R2 was significantly lower in MM patients than in controls (7518±2119 vs. 8725±1281 pg/ml, respectively; p<0.001). We observed an inverse correlation between length of treatment and the level of sIL-6R, and TGF-β1 in plasma. Conclusions. Plasma levels of HGF, b-FGF, IL-6 and sIL-6R in MM patients were higher when compared to the control group. Antineoplastic therapy leads to a time-dependent decrease in plasma levels of sIL-6R, and TGF-β1 in MM patients. Blood plasma level of HGF is an optimal measure to differentiate patients in whom disease is progressing versus patients who respond to therapy. Key words: b-FGF, cytokines, HGF, interleukin-6, multiple myeloma. Introduction Recent studies have confirmed the importance of likely the inhibition of apoptosis of myeloma cells. It soluble cytokines and their receptors in the biology of has been shown that the level of soluble receptors for multiple myeloma (MM) [1-3]. The principal mecha- IL-6 (sIL-6R) is elevated in myeloma patients com- nism of action of interleukin-6 (IL-6) in MM is most pared to healthy subjects, and its level correlates with http://www.jcancer.org Journal of Cancer 2014, Vol. 5 519 disease severity [3,4]. Currently, the serum level of women (54.3%) and 16 men (45.7%) F/M ratio = 1.2. sIL-6R is considered to be one of the prognostic fac- The diagnosis of MM was based on cytologic exami- tors in MM [4]. Vascular endothelial growth factor nation of bone marrow aspirate revealing at least 10% (VEGF) is one of the strongest drivers of angiogenesis. plasmocytes, the presence of monoclonal proteins in In MM, the binding of VEGF with its receptors, serum or urine, and bone osteolytic lesions. Patients VEGF-R1 and VEGF-R2, induces angiogenesis and with MM were divided into 2 groups, designated N leads to exponential growth of the tumour. Further- for newly diagnosed, previously untreated, and S for more, with the activation of these receptors, there is patients undergoing antiproliferative treatment. increased expression of integrins on the cell surface, Group N consisted of 29 patients (38.2%), while group which facilitates adhesion and migration [6, 7, 8]. In S consisted of 47 people (61.8%). We subdivided MM, the serum level of basic fibroblast growth factor group S into three groups, based on length of treat- (b-FGF) increases with disease progression. It was ment: S1 included patients undergoing treatment for 1 also found that myeloma cells express surface recep- to 2 years (n=13), S2 comprised patients undergoing tor FGF-R3 (which is not found on normal lymphoid treatment for 2 to 3 years (n=11), and S3 consisted of cells), divide more rapidly and undergo apoptosis less patients undergoing treatment for longer than 3 years frequently than cells without FGF-R3. Effective anti- (n=23). Additionally, any patient in group S under- proliferative treatment often causes a reduction in going treatment for more than a year was evaluated b-FGF levels in the serum of patients with MM for response to antiproliferative therapy. Patients with [1,9,10]. Transforming growth factor-β1 (TGF-β1) is MM were treated according to the guidelines of the synthesized by almost all cells of the body. The in- Polish Myeloma Group. For patients under 65 years of creased microvascular network in the bone marrow of age, first line treatment consisted of the CTD protocol patients with MM is likely the result of the plasma (cyclophosphamide, thalidomide, and dexame- secretion of TGF-β1, which stimulates the release of thasone) followed by CTX and G-CSF combined with platelet derived growth factor and thereby enhances the auto-PBSCT procedure. Throughout treatment we angiogenesis [11]. Hepatocyte growth factor (HGF) continued thalidomide. In cases of disease recurrence, has mitogenic, chemotactic, and morphogenic prop- treatment consisted of bortezomib or lenalidomide in erties. It has a significant effect on the morphogenesis many cases. Patients over 65 years of age were treated of new blood vessels and bone marrow stroma, and it either with the MPT (melphalan, prednisone, and stimulates the synthesis of angiogenic factors. Ele- thalidomide) or VMP (bortezomib, melphalan and vated levels of HGF in the serum of patients with MM prednisone) protocols. In cases of disease progression, is associated with an unfavourable prognosis. Nu- lenalidomide and dexamethasone were given [17]. We merous studies have shown that HGF is involved in evaluated whether there was progression of disease, the progression of MM, including damage to bone, resistance to treatment, or if treatment had a positive angiogenesis, and myeloma cell adhesion to bone effect. These analyses were based on: assessment of marrow stroma [12,13]. Studies indicate the im- bone marrow (the percentage of plasma cells in bone portance of the HGF-c-MET axis in the stimulation of marrow biopsy), protein parameters (serum protein proliferation and inhibition of apoptosis in MM cells electrophoresis), biochemical parameters (serum [4,15,16]. C-reactive protein - CRP, β2 microglobulin, calcium), The aim of this study was to compare the plasma and complete blood count. During our testing we levels of cytokines IL-6, VEGF, b-FGF, TGF-β1, HGF, were unable to evaluate the clinical outcome of and soluble receptors sIL-6R and sVEGF-R2 between treatment in 6 patients, and therefore testing was patients with MM and healthy volunteers. conducted on the remaining group of 41 patients. Of these remaining patients 23 positively responded to Patients and methods treatment while 18 patients showed progressive MM Clinical characteristics of the study group which was resistant to therapy. The study was ap- proved by the local Ethics Committee. The study comprised 76 patients aged 22 to 77 years (mean age 60 years, SD ± 10) with MM treated at Blood and plasma analysis the Department of Haematology, University Hospital, Blood samples were collected between 7:30 and Krakow, Poland. The control group consisted of 35 8:30 hours in sterile Vacutainer tubes (Becton Dickin- healthy volunteers aged 20 to 63 years (mean age 33 son, New Jersey, USA) which contained an anticoag- years, SD ± 10). Both test and control groups were ulant (EDTA). The tubes were then centrifuged for 10 similar with respect to gender distribution. The group minutes at 1,000 RPM. Plasma was pipetted into ster- of patients with MM included 38 women and 38 men, ile tubes (Nunc, Roskilde, Denmark) and stored at F/M ratio = 1. The control group consisted of 19 -70°C until analysis was performed. Biochemical as- http://www.jcancer.org Journal of Cancer 2014, Vol. 5 520 says of lactate dehydrogenase (LDH), blood urea, to initiation of treatment. Conversely, we observed a creatinine, total calcium concentration in both groups drop in plasma levels of sIL-6R and TGF- β1 as dura- and CRP, β2 microglobulins, serum protein electro- tion of disease and treatment increased. Decreased phoresis in MM group were performed using stand- levels of VEGF, HGF, and b-FGF were noticed after ard methods. Results of blood counts were obtained initiation of therapy. Values of sVEGF-R2 were simi- via photo-optical and conductivity methods using a lar in all analyzed subgroups.
Load more

Recommended publications
  • Blood Coagulation and Haemostasis: a Review*
    BLOOD COAGULATION AND HAEMOSTASIS: A REVIEW* E. M. RODF_~QUE,M.D. AND J. E. WYNANDS, M.D., C.IVI.~ FnOM THE V~Y F_~aLY STUVmS of this subject, many controversies existed regard- ing the various factors and mechanisms involved in the dotting process. One simply has to review the current literature and note the complex, often variable terminology, and the differing opinions of several workers in this field to realize that many of the former controversies are still present. However, many facts have been firmly established. This review will deal primarily with these facts and will mention the disputed points only when they appear pertinent to a better under- standing of the problems of controlling haemorrhage. Various factors are involved in the haemostatic process; the established ones include (1) the extravascular tissues; (2) the vasculature itself, the size and type of vessel being important; (3) the number of functioning platelets, and (4) the plasma coagulation system,x,2 THE ErmAVASCtrLABTISSUES While the extravaseular tissues do not play a major role in the control of bleeding, yet "their integrity and/or the variations in the resistance they offer to escaping blood may determine the bleeding response of a particular part of the body after injury. The "black eye' is a well-known example."2 In other situations in which there is easy bruisability, as in the aged, in poor nutrition, in some women, and in disease states such as the Ehlers-Danlos syndrome, it is likely that poor extravascular support is a deciding or contributing factor. 2 THE V~CULATVBE Previous to the more advanced and tested knowledge of today, abnormal vascular function was implicated as the basic pathogenetic factor in a variety of bleeding disorders.
    [Show full text]
  • Patho-Physiology of Kallikrein System
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 10, No. 3 Copyright (£) 1980, Institute for Clinical Science, Inc. Patho-Physiology of Kallikrein System ROBERT W. COLMAN, M.D. Thrombosis Center and Hematology ¡Oncology, Section of the Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140 ABSTRACT The properties of the contact factors, factor XII, high molecular weight kininogen and prekallikrein are described as well as the abnormalities in the hereditary deficiencies of these proteins. The interactions of each of these proteins with the other as well as their regulation by plasma proteolytic inhibitors such as Cl inhibitor and antithrombin III are delineated. Biochemical techniques for measuring this system are discussed. Condi­ tions associated with abnormal synthesis of these proteins are described. Diseases in which increased kinin formation has been documented as well as disorders where there is strong evidence for the activation of kallikrein are presented. Further knowledge of this system should increase our under­ standing of its pathophysiological alterations. Introduction illustrates the various control mechanism possible in proteolysis, including activa­ The plasma proteolytic enzyme systems tion of inactive precursors, positive feed­ of coagulation, fibrinolysis and kinin for­ back, stochiometric inhibition, multistep mation have been categorized as a “tan­ amplification and enzymatic degradation gled web.” The three interlocking net­ of active products. works are linked together in two ways. Factor XII (a beta globulin), molecular First, the initiating pathways are common weight 90,000, is first converted to an ac­ and factor XII (Hageman) factor is a pro­ tive derivative of the same size, factor tein intimately involved in all.
    [Show full text]
  • Gamma Globulin”
    CLINICAL APPLICATION OF A SIMPLE METHOD FOR ESTIMATING “GAMMA GLOBULIN” B. V. Jager, Margaret Nickerson J Clin Invest. 1948;27(2):231-238. https://doi.org/10.1172/JCI101938. Research Article Find the latest version: https://jci.me/101938/pdf CLINICAL APPLICATION OF A SIMPLE METHOD FOR ESTIMATING "GAMMA GLOBULIN" 1 By B. V. JAGER AND MARGARET NICKERSON (From the Department of Medicine, School of Medicine, University of Utah, Salt Lake City) (Received for publication August 11, 1947) The electrophoretic technique offers the most cipitate is finely emulsified in 3.0 ml. of 33.3 per cent accurate method for serum fractionation. This saturated ammonium sulfate. The tube is recentrifuged for 30 minutes and the supernatant fluid is discarded. permits a quantitative separation of serum into The precipitate is dissolved in 10 ml. of saline and an albumin and into three major globulin fractions aliquot is employed to determine its protein content, using which are designated as alpha, beta and gamma a biuret method such as that of Weichselbaum (2). components. In recent years electrophoretic anal- Triplicate determinations may be made with an *yses of serum proteins have been performed by accuracy of + 2 per cent. Electrophoretic studies many investigators in a variety of diseases. The indicate that 73 to 83 per cent of this protein accumulated data from these studies have now at- fraction consists of gamma globulin, the remainder tained sufficient size and agreement that they may consisting of alpha and beta globulins. From 70 to be of value as an aid in the differential diagnosis 82 per cent of the total gamma globulin present of certain diseases or for following the course of in the serum is recovered in this fraction.
    [Show full text]
  • 259 Subpart F—Immunological Test Systems
    Food and Drug Administration, HHS § 866.5065 subpart E of part 807 of this chapter used while measuring various kinds of, subject to the limitations in § 866.9. or parts of, protein molecules by var- ious immunochemical techniques, such [47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25047, June 12, 1989; 66 FR 38792, July 25, as immunoelectrophoresis, immuno- 2001] diffusion, or chromatography. (b) Classification. Class I (general con- § 866.4800 Radial immunodiffusion trols). The device is exempt from the plate. premarket notification procedures in (a) Identification. A radial subpart E of part 807 of this chapter immunodiffusion plate for clinical use subject to the limitations in § 866.9. is a device that consists of a plastic [47 FR 50823, Nov. 9, 1982, as amended at 54 plate to which agar gel containing FR 25047, June 12, 1989; 66 FR 38792, July 25, antiserum is added. In radial 2001] immunodiffusion, antigens migrate through gel which originally contains Subpart F—Immunological Test specific antibodies. As the reagents Systems come in contact with each other, they combine to form a precipitate that is § 866.5040 Albumin immunological test trapped in the gel matrix and immo- system. bilized. (a) Identification. An albumin immun- (b) Classification. Class I (general con- ological test system is a device that trols). The device is exempt from the consists of the reagents used to meas- premarket notification procedures in ure by immunochemical techniques the subpart E of part 807 of this chapter albumin (a plasma protein) in serum subject to the limitations in § 866.9.
    [Show full text]
  • Raw Materials for R&D and Manufacturing
    Raw Materials for R&D and Manufacturing Native Proteins (human), Recombinant Proteins From Serum / Plasma or Manufactured in SF19, HEK293, e.coli Serum Free Freeze Protection, Serum Free Media Manufactured under cGMP upon request Sera Semipurified Antisera for Adsorption Purposes Control sera, Depleted Sera Origin: Human; bovine, ovine; goat, rabbit, donkey Assay and Cell Culture Supplements Growth Factors BSA Cohn V fraction: Origin Australia, USA, New Zealand; HSA in solution (25%) Trehalose ,Ectoins, Ready-to-Use Osmolytes Complete / Fragment Polyclonal Antibodies Ig E: human; Ig G goat, rat, rabbit, mouse, human cross-adsorbed antibodies, custom-manufactured, against chicken, human, mouse, rabbit, rat Ig A;G;M; conjugates horse radish peroxidase; fluorescence labels incl GFP analogs ARTIMMUN ANALYTIK GmbH Benzstrasse 6 D 65779 Kelkheim Tel 49-6195 674 724 Fax 49-6195-674 722 info at artimmun.eu Human Native Proteins (Bulk packing) Human Plasma Proteins Immunoglobulin M, Myeloma Albumin Immunoglobulin M, Fc5mu Fragment Alpha-1 Acid Glycoprotein Immunoglobulin M, mu Chain Alpha-1-Antichymotrypsin Kallikrein Alpha-1-Antitrypsin Kininogen, HMW Alpha-2-Antiplasmin Kininogen, LMW Alpha-2-HS-Glycoprotein Lipoprotein a, [Lp(a)] Alpha-2-Macroglobulin Lipoprotein, High Density Antithrombin III Lipoprotein, Intermediate Density Apolipoprotein AI Lipoprotein, Low Density Apolipoprotein AII Lipoprotein, Very Low Density Apolipoprotein B Plasmin Apolipoprotein CI Plasminogen Apolipoprotein CII Prealbumin Apolipoprotein CIII Apolipoprotein E Human
    [Show full text]
  • Cholesterol and Protein Studies in Early Stages of Traumatic Paraplegia and Tetraplegia
    CHOLESTEROL AND PROTEIN STUDIES IN EARLY STAGES OF TRAUMATIC PARAPLEGIA AND TETRAPLEGIA K. EDWARDS, FRANKEL, By B. B. SC., H. , M.B., B.S., M.R.C.P., and LUDWIG GUTTMANN, .E. SirNational Spinal Injuries Centre,C.B StokeM.D. Mandeville, F.R.C.P. ,Hospital, F.R.C.S. Aylesbury, England TRAUMATIC paraplegia and tetraplegia following fractures and fracture-dislocations of the vertebral column is inevitably associated in the first instance with primary shock, severe local damage and profound changes of the function of the autonomic mechanisms. As a result of this disaster, homeostasis is thrown into chaos, especially in transection or severe incomplete lesions of the cervical cord, and the regulatory function of the nervous system in maintaining a suitable internal environment in these high lesions is greatly reduced. Therefore it was thought worth while to study the behaviour of serum proteins and cholesterol in relation to some basic haematology in the immediate and early stages of traumatic para­ plegia and tetraplegia. Reports in the literature of similar comparative studies in acute traumatic lesions of the spinal cord are lacking but similar studies, including those of Woodford-Williams et al. (1962) have been performed in other types of afflictions. These authors examined the same variables in a series of elderly patients immediatelyafter cardiac or cerebral infarction, surgical operations, and congestive heart failure. Clinical Material. Twenty-six patients-21 male and 5 female-with spinal cord injuries as a result of vertebral fractures or fracture-dislocations were investigated, all of whom were admitted to the National Spinal Injuries Centre on or close to their date of injury.
    [Show full text]
  • Molecular Mechanisms of Relationship Between Blood Plasma Beta-Globulins and Protein Markers of Renal and Bladder Cancer
    BioNanoSci. (2015) 5:84–90 DOI 10.1007/s12668-015-0165-x Molecular Mechanisms of Relationship Between Blood Plasma Beta-globulins and Protein Markers of Renal and Bladder Cancer E. I. Erlykina & L. M. Obukhova & A. B. Yazykova & V. F. Rossokhin & T. N. Gorshkova & V. P. Frantsuzova Published online: 14 March 2015 # Springer Science+Business Media New York 2015 Abstract The aim of the investigation was to enhance the CD1b). Analysis of the relationship between individual blood screening diagnosis of epithelial tissue malignant tumors, the plasma β-globulin proteins and identified tissue markers molecular relationship between blood plasma protein fractions, showed the greatest number of protein-protein interactions for and carcinogenesis tissue markers in renal and bladder cancer. proteins with reduced level in malignant tumors: transferrin had Blood plasma of 87 cancer patients, not previously subjected to 11-interactor proteins, as well as angiostatin had only 4. The antitumor treatment, and 9 patients with psoriasis was studied. involvement of protein markers interacting with individual pro- Blood plasma of 52 healthy people was used as control. Bio- teins of blood plasma β-globulin fractions in the signaling path- chemical parameters were evaluated on the analyzer BKoneLab ways that regulate apoptosis and cell proliferation was shown. 20 / 20i^ (Finland). Statistical analysis was performed using the Changes in the content of β-globulins of blood plasma in ma- software Statistica 6.0. Network construction of protein-protein lignant tumors of epithelial tissues, including renal and epithe- interactions was performed by means of Cytoscape software, lial cancer are suggested to be considered as specific pathogenic using databases STRING, BioGrid, SwissPro.
    [Show full text]
  • Immunofluorescent Studies in Adult Celiac Disease
    Immunofluorescent Studies in Adult Celiac Disease Walter Rubin, … , Marvin H. Sleisenger, Graham H. Jeffries J Clin Invest. 1965;44(3):475-485. https://doi.org/10.1172/JCI105161. Research Article Find the latest version: https://jci.me/105161/pdf Journal of Clinical Investigation Vol. 44, No. 3, 1965 Immunofluorescent Studies in Adult Celiac Disease * WALTER RUBIN,t ANTHONY STEPHEN FAUCI, MARVIN H. SLEISENGER, AND GRAHAM H. JEFFRIES t WITH THE TECHNICAL ASSISTANCE OF SUE MARGOLIS (From the Department of Medicine, Cornell University Medical College, New York, N. Y.) The etiology of childhood and adult celiac dis- Two hypotheses of the mechanism of gluten ease is not known. It has been established, how- toxicity in celiac patients have been proposed ever, that gluten, a complex heterogeneous pro- (3). One hypothesis is that celiac disease is the tein in wheat and other cereal grains, plays a sig- result of an inborn error of metabolism-a defi- nificant role in the pathogenesis of the disease, and ciency of a specific peptidase in the intestinal mu- that the harmful factor resides in gliadin, the al- cosa, which results in the accumulation of indi- cohol soluble fraction of gluten (1-4). Treatment gestible toxic peptides of gliadin. Two recent of celiac disease with a gluten-free diet results in observations, however, have failed to demonstrate clinical and biochemical improvement usually ac- a specific peptidase deficiency in the small intes- companied by a decrease in the severity of the tinal mucosa of celiac patients (10, 11). pathologic lesion in the proximal small intestinal The second hypothesis suggests that celiac dis- mucosa.
    [Show full text]
  • The Electrophoretic Analyses of the Serum Proteins in Diseases of the Liver
    THE ELECTROPHORETIC ANALYSES OF THE SERUM PROTEINS IN DISEASES OF THE LIVER Seymour J. Gray, E. S. Guzman Barron J Clin Invest. 1943;22(2):191-200. https://doi.org/10.1172/JCI101382. Research Article Find the latest version: https://jci.me/101382/pdf THE ELECTROPHORETIC ANALYSES OF THE SERUM PROTEINS IN DISEASES OF THE LIVER By SEYMOUR J. GRAY AND E. S. GUZMAN BARRON (From the Chemical Division of the Department of Medicine, University of Chicago, Chicago) (Received for publication September 4, 1942) The intimate association of the liver with the compared. Patients with varying degrees of liver maintenance of normal serum proteins is well insufficiency were studied in each group. established. An increase in serum globulin, with inversion of the albumin-globulin ratio, is a com- METHOD mon finding in cirrhosis of the liver, but normal The blood samples were obtained from the patients serum proteins are observed frequently in the before breakfast. The serum was diluted with 3 parts of veronal buffer made by mixture of the required amounts acute parenchymatous diseases of the liver like of 0.025 M veronal, 0.025 M HCI, and 0.025 M NaCl to catarrhal jaundice and arsenical hepatitis (1). a pH value of 7.8 at 250 C., and dialyzed against several The serum protein fractions in cancer of the liver liters of this buffer for 3 to 4 days, at 30 C., the buffer are quite variable. being changed daily. The protein solution was then Determination of the serum proteins by the centrifuged at 30 C. before being introduced into the electrophoresis cell.
    [Show full text]
  • S .' 30/3 7 CONTRACEPTION
    S / 30 / s .' 30/3 7 CONTRACEPTION EFFECTS OF ORAL CONTRACEPTION ON LIVER FUNCTION TESTS AND SERUM PROTEINS IN WOMEN WITH PAST VIRAL HEPATITIS M.M. Shaaban*, W.A. Hammad, M.F. Fathalla, S.A. Ghaneimah, M.M. El-Sharkawy T.H. Salim, M.Y. Ali, W.C. Liao** and S.C. Smith** Assiut University, Departments of Obstetrics and Gynecology, Biochemistry and Tropical Medicine, P. 0. Box 30, Assiut, Egypt and ** International Fertility Research Program, Research Triangle Park, North Carolina, U. S. A. ABSTRACT Forty-three women who had had viral hepatitis one or more years ago and 35 healthy women who were age and parity matched were given an oral contraceptive containing 0.05ig ethinyl estradiol and 0.5mg levonorgestrel for six consecutive months. Liver function tests (serum bilirubin, SGOT, SGPT aid serum alkaline phosphatase) and serum proteins (total, albumin, globulins, ceruloplasmin, haptoglobin and alpha-1 antitrypsin) were measured before beginning trkeatment and after three and six months of use. Past hepatitis won!n experienced increased unconjugated bilirubin, SGOT, SGPT and alkaline phosphatase levels throughout the six months while the control women showed less pronounced changes during the first three months with tendency to reversion to normal during the subsequent three months; the group X time of test interactions were significant­ ly different between the two groups. Serum haptoglobin decreased significantly in both groups but the past-hepatitis group showed a more persistent change with time. Changes also occurred in serum albumin, alpha-1 and beta globulins, cerulo­ plasmin but without group effect or group X time interactions. * To whom correspondence should be adressed.
    [Show full text]
  • International Standardization of Bed Rest Standard Measures
    International Standardization of Bed Rest Standard Measures Ronita L. Cromwell, PhD Flight Analogs Project Scientist Standardization of Bed Rest Studies ► International Multidisciplinary Artificial Gravity (IMAG) project (2005) ► Standardization of AG studies ► Screening ► Standard conditions ► Data management ---------------------------------------------------------------------------------------------------------------------------- ► 2 Standardization of Bed Rest Studies ► International Countermeasures Working Group (ICMWG) ► International Academy of Astronautics Study Group ► International Standards for Bed Rest Studies q Co-Chairs: Patrik Sunblad (ESA) and Oleg Orlov (IBMP) q Secretary: Dave Francisco (NASA) q Overall Goal: To define and agree internationally, on standard conditions and basic, standard measurements for spaceflight related bed rest studies. q Standard Conditions Assessment –Oliver Angerer (ESA) q Meeting February 1-2, 20 1 0 at USRA q Standard Measures Assessment – Ronita Cromwell (NASA) q Patrik Sunblad (ESA), Irina Larina (IBMP) ---------------------------------------------------------------------------------------------------------------------------- 0 3 Standard............... .............................................................................................................................. Measures Assessment ► Identified discipline experts from each agency (NASA, ESA, IBMP) to assess the standard measures. Cardiovascular Richard Hughson Steve Platts Olga Vinogradova Muscle Joern Rittweger Lori Ploutz-Snyder
    [Show full text]
  • Grass Pollens • Almond Is the Edible Seed of a Drupe in This Series
    Legumes, Nuts & Seeds Allergy – Which allergens? Author: Dr Harris Steinman, Allergy Resources International, P O Box 565, Milnerton 7435, South Africa, [email protected]. All rights reserved. No part of this publication may be reproduced in any form without the written consent of Phadia AB. ©Phadia AB, 2008 Design: RAK Design AB, 2008 Printed by: X-O Graf Tryckeri AB, Uppsala, Sweden ISBN 91-970475-5-4 Contents Introduction ............................................................................. 5 f20 Almond (Amygdalus communis) ..................................... 9 f6 Barley (Hordeum vulgare) ............................................ 15 f310 Blue vetch (Lathyrus sativus) ....................................... 22 f18 Brazil nut (Bertholletia excelsa) ................................... 26 f11 Buckwheat (Fagopyrum esculentum) ............................ 32 f202 Cashew nut (Anacardium occidentale) .......................... 41 f309 Chick pea (Cicer arietinus) .......................................... 49 f36 Coconut (Cocos nucifera) ............................................. 54 f55 Common millet (Panicum milliaceum) .......................... 59 f305 Fenugreek (Trigonella foenum-graecum) ........................ 64 f56 Foxtail millet (Setaria italica) ....................................... 67 f79 Gluten (from Triticum aestivum) ................................... 70 f315 Green bean (Phaseolus vulgaris) ................................... 77 f17 Hazel nut (Corylus avellana) .......................................
    [Show full text]